Biopunk 2037: Independent Skeptical Reality Check

Date: 2026-05-31
Scope: bioengineered organs, xenotransplantation, organoids/bodyoids, regenerative medicine, nerve reconnection, regulatory arbitrage, and cultivated meat.
Method: independent from-scratch review; I read only the supplied scenario file for context and did not read other repository docs.

Bottom Line

DEMONSTRATED: the clinically real center of gravity is not lab-grown bodies; it is gene-edited pig organs, extracorporeal bioengineered organ-assist devices, and neurostimulation/BCI routing around spinal injury. Pig kidneys have now functioned in living humans for months, United Therapeutics has an FDA-cleared UKidney trial, eGenesis has an FDA-cleared EGEN-2784 kidney IND, Miromatrix/United Therapeutics has completed a five-patient phase 1 miroliverELAP external liver-assist study, and ONWARD's noninvasive ARC-EX spinal-cord stimulator has FDA De Novo authorization. Sources: United Therapeutics UKidney IND source, eGenesis EGEN-2784 IND source, miroliverELAP phase 1 source, ONWARD ARC-EX FDA authorization source.

SPECULATIVE: whole acephalic human bodies, "organ sacs," and routine brain-to-body transfer by 2037 are still highly speculative. The hard blockers are not just money; they include whole-body developmental control, long-duration ectogenesis, vascularization/perfusion at organ scale, immune/endocrine integration, and CNS axon topographic reconnection. Bodyoid proposals exist, and R3 Bio has real startup visibility, but MIT Technology Review reported it had not found evidence that R3 had created even an organ sack, much less a brainless human clone source.

My independent estimate: Biopunk-2037 as personalized organ replacement and pig/bioengineered organ supply: plausible, P ~45-65%. Biopunk-2037 as lab-grown spare bodies with routine brain integration: unlikely, P ~3-8%.

1. Xenotransplantation: Pig Organs In Humans

Verdict: SUPPORTED, with serious durability uncertainty. This is the most real node in the scenario.

DEMONSTRATED: United Therapeutics/Revivicor received FDA IND clearance for the UKidney xenotransplantation clinical trial on February 3, 2025; the company described this as a first clinical trial of a xenokidney for ESRD patients source. ClinicalTrials.gov lists the United Therapeutics EXPAND study as NCT06878560 and says participants receive xenotransplantation followed by a 24-week post-transplant follow-up and long-term follow-up for participant survival, 10GE Xenokidney survival, and zoonotic infection screening source. United Therapeutics' investor presentation described an initial six-patient cohort and an expanded cohort toward roughly 50 patients, with 24-week endpoints including survival, function, and quality of life source.

DEMONSTRATED: eGenesis announced FDA clearance of an IND for EGEN-2784, a genetically engineered porcine-derived kidney, on September 8, 2025; the company says the IND supports a phase 1/2/3 study assessing safety, tolerability, and efficacy at 24 weeks in ESKD patients who are at least 50, dialysis-dependent, and waitlisted source. eGenesis says EGEN-2784 uses three classes of edits: removal of three glycan antigens, insertion of seven human transgenes, and inactivation of porcine endogenous retroviruses source.

DEMONSTRATED human case history:

Skeptical read: xenotransplantation is no longer vapor. The moving target is durability. The best public living-human kidney case as of late 2025 was 271 days, not years source. That supports a 2037 world with pig organs as bridges, high-risk alternatives, and maybe selected routine transplants. It does not yet demonstrate "off-the-shelf organs like spare parts."

Independent P estimates:

2. Bioengineered / Decellularized And Recellularized Organs

Verdict: SUPPORTED for organ-assist and ectopic mini-organ approaches; OPEN for whole transplantable organs.

DEMONSTRATED: United Therapeutics acquired Miromatrix in 2023; the acquisition release says Miromatrix was developing bioengineered organs composed of human cells and would add decellularization/recellularization programs to United Therapeutics' organ-manufacturing stack source. United Therapeutics' SEC filing says the acquisition closed on December 13, 2023 and describes a mirokidney milestone tied to first implantation of the fully implantable kidney product by the end of 2025 source. I did not find evidence that the fully implantable mirokidney milestone was achieved by end-2025; United Therapeutics' January 2026 miroliverELAP release describes mirokidney as still in development source.

DEMONSTRATED: miroliverELAP is an external liver assist product, not an implanted liver. United Therapeutics says it consists of an external blood circuit and a single-use bioengineered liver made by seeding a decellularized porcine liver scaffold with human endothelial and liver cells from donated livers unsuitable for transplant source. The company announced positive phase 1 results on January 26, 2026: five acute liver failure patients who were not transplant candidates were treated for at least 44 hours, the safety study met its primary endpoint of survival during treatment, and no unexpected serious adverse events attributable to miroliverELAP were reported over a 32-day follow-up source. The same release says United Therapeutics plans to initiate phase 2 source.

DEMONSTRATED: LyGenesis is testing ectopic liver growth in lymph nodes, not whole-organ fabrication. ClinicalTrials.gov lists NCT04496479 as a recruiting phase 2a open-label dose-escalation study of allogeneic hepatocyte transplantation into periduodenal lymph nodes for end-stage liver disease, up to 12 subjects source. LyGenesis announced first patient dosing in this phase 2a trial on April 2, 2024 and described lymph nodes as living bioreactors for ectopic liver tissue source.

Skeptical read: decellularized scaffolds are real because native vascular architecture is being reused. The clinically demonstrated near-term product is "temporary organ support," not "new transplantable human organ." LyGenesis is even more interesting for the scenario: it sidesteps whole-organ printing by recruiting the host as bioreactor. But it is still early phase 2a, open-label, small-N, and focused on liver tissue support source.

Independent P estimates:

3. Lab-Grown Organs From Scratch / Organoids

Verdict: UNDERCUT if the claim is transplantable whole organs by 2037; SUPPORTED if the claim is disease models, toxicity testing, organ chips, patches, and small grafts.

DEMONSTRATED: organoids are excellent models but are not miniature transplantable organs. Reviews describe organoids as 3D culture systems that mimic some structural and functional features of organs source. Vascularization remains the bottleneck because most living cells are within about 100-200 micrometers of capillaries in vivo, and engineered tissues must keep cells within similar diffusion distances or perfuse them source, source. Reviews of organoid vascularization say lack of functional vascularization limits organoid maturation and size source.

DEMONSTRATED: a rough "1 mm" ceiling appears because oxygen/nutrient diffusion creates necrotic cores in larger unperfused organoids; vascularization reviews and engineering papers place the relevant diffusion distance around 100-200 micrometers and discuss 1-2 mm as an upper range for constructs that cannot rely on diffusion alone source, source. The exact number varies by cell type, density, geometry, oxygen tension, and medium flow, so I treat "150-200 micrometers" as the conservative engineering constraint and "about 1 mm" as the practical unperfused-organoid size problem rather than a universal law source.

DEMONSTRATED: 3D bioprinting is advancing but still lacks transplant-ready whole organs. A 2025 review says a central clinical-translation obstacle is the lack of benchmarks for minimal physiological performance and that transplant-ready constructs need vascular networks matching human microcirculation source. Stanford reported vascularized heart and liver organoids with tiny vessel-like networks in 2025, which is promising for models and future regenerative therapies, but that announcement is not evidence of transplantable organs source.

Skeptical read: "we can grow an organoid" is routinely overclaimed as "we can grow an organ." The missing pieces are vascular tree, bile/urine/airway/drainage architecture, innervation, stromal and immune compartment maturity, mechanical strength, scale-up reproducibility, and surgical integration. Bioprinting can help pattern tissues; it does not magically recapitulate organ development.

Independent P estimates:

4. "Organ Sacs," Acephalic Bodies, Bodyoids

Verdict: mostly UNDERCUT by 2026 evidence. There is a concept paper, startup activity, and ethical debate; there is no demonstrated whole-body cultivation platform.

DEMONSTRATED: the "bodyoid" concept is public. A 2025 MIT Technology Review essay by Carsten Charlesworth, Henry Greely, and Hiromitsu Nakauchi proposed living human bodies without neural components that allow thought, awareness, or pain as possible sources of research material and organs source. Philosophy & Technology commentaries in 2025-2026 describe bodyoids as engineered human bodies lacking neural architecture required for consciousness and note both feasibility and moral objections source, source.

DEMONSTRATED: R3 Bio publicly presents itself more modestly as a company developing cell-based research platforms, cellular reprogramming, stem-cell-derived model systems, and New Approach Methodologies for preclinical research, with a long-term interest in full-scale human organ fabrication source. Wired reported R3 Bio wanted nonsentient human organ systems or "organ sacks" as alternatives to animal testing and possible sources of tissues/organs source. MIT Technology Review, via Center for Genetics and Society republication, reported that R3 founder John Schloendorn had also pitched "brainless clones" or backup bodies, but also reported that MIT Technology Review had not found evidence R3 had created an organ sack or brainless human clone source.

UNCERTAIN: the user asked about Kind Biotechnology. I found secondary references tying Kind Biotechnology to organ-sack/bodyoid patent or startup activity, but not enough primary evidence in this pass to treat it as a demonstrated technical program. I would not lean on Kind as an evidentiary anchor without a patent, company filing, or direct technical disclosure.

DEMONSTRATED bottleneck: whole-body cultivation needs either pregnancy or ectogenesis. The best-known artificial-womb lineage, CHOP's EXTEND/Biobag system, supported extremely premature lambs for up to about four weeks and corresponds biologically to supporting very premature infants, not de novo gestation from embryo to birth source, source. The FDA convened a Pediatric Advisory Committee meeting in September 2023 to discuss artificial-womb technologies for extremely preterm infants, highlighting scientific, logistical, and ethical issues before human trials source, source.

Skeptical read: bodyoids are plausible enough to discuss ethically, not plausible enough to bank worldbuilding on. The phrase "organ sac" hides a giant developmental biology problem: a body is not a bag of independently grown parts; it is a coordinated embryo/fetus/neonate/adolescent developmental program with brain, endocrine, immune, vascular, musculoskeletal, and microbiome interactions. Removing or suppressing brain development is not a minor deletion. Even if sentience is prevented, the body must still breathe or be perfused, regulate hormones, grow bones and vessels, clear waste, avoid tumors, avoid malformations, and mature organs to adult function.

Independent P estimates:

5. Nerve / Spinal Reconnection

Verdict: SUPPORTED for routing around damaged pathways; UNDERCUT for whole-spinal-cord reconnection or body-transplant integration.

DEMONSTRATED: Courtine, Bloch, and collaborators published a 2023 Nature case study of a wireless brain-spine interface that restored communication between cortical signals and epidural spinal stimulation programs, enabling one person with chronic tetraplegia to regain standing and walking after spinal-cord injury source. Nature Electronics summarized that the system could be calibrated in under five minutes, remained reliable over about a year, and improved neurological recovery even when turned off source. This is a real "digital bridge," not hype; it is also a single-participant demonstration, not a general spinal reconnection cure source.

DEMONSTRATED: epidural electrical stimulation has restored walking-related function in multiple chronic SCI patients under intensive rehabilitation. A 2022 Nature paper reported that spatiotemporal epidural electrical stimulation during neurorehabilitation restored walking in nine individuals with chronic spinal cord injury source. Earlier Nature work in 2018 reported targeted spinal cord stimulation enabling voluntary control of walking in individuals with chronic injury and permanent motor deficits or paralysis source.

DEMONSTRATED: ONWARD Medical has commercialized a noninvasive stimulation branch. The ARC-EX system received FDA De Novo classification and U.S. market authorization in December 2024 for chronic SCI, and ONWARD describes it as improving hand strength and sensation after chronic spinal cord injury source. ONWARD's product page says ARC-EX is FDA cleared in the United States and CE marked in Europe for chronic cervical spinal cord injury hand sensation/strength source.

DEMONSTRATED but preclinical: Stupp's supramolecular peptide scaffold work is important but not yet a human spinal-cord repair therapy. The 2021 Science paper reported bioactive scaffolds with enhanced supramolecular motion promoted recovery after spinal cord injury in mice source.

SPECULATIVE: none of these solve the "cut the head/brain from one body and reconnect it to another body" problem. Brain-spine interfaces bypass an injury by decoding intention and stimulating spinal circuits below the lesion; they do not physically reconnect every axon with correct topography source. Spinal-cord repair scaffolds aim to improve regeneration and functional recovery in injury contexts; they do not demonstrate full adult CNS severance repair across millions of fibers source.

The ~1M-axon problem: this number is an order-of-magnitude framing, not a sourced exact count for any proposed body-transplant interface. The biological issue is that corticospinal, sensory, autonomic, propriospinal, and pain pathways are topographically organized; useful full-body integration would require axons to cross a lesion, choose correct tracts, synapse on correct targets, remyelinate, and avoid maladaptive pain/spasticity. The closest demonstrated human workaround is BCI plus stimulation, which maps intent to stimulation programs, not anatomical reconnection source.

Independent P estimates:

6. Regulatory Path

Verdict: OPEN for accelerated regenerative medicine; UNDERCUT for a broad legal "bio emergency pathway" unless Congress creates one.

DEMONSTRATED: the 21st Century Cures Act created RMAT designation. FDA says RMAT eligibility requires a regenerative medicine therapy, a serious or life-threatening disease or condition, and preliminary clinical evidence suggesting the therapy may address unmet medical needs source. FDA also says certain human gene therapies and xenogeneic cell products may meet the regenerative medicine therapy definition source.

DEMONSTRATED: expanded access/compassionate use already exists for serious or immediately life-threatening conditions when no comparable satisfactory alternatives exist and potential benefit justifies risk source. FDA has separate expanded-access mechanisms for investigational devices, including emergency use when no alternative exists and there is no time to obtain FDA approval through normal procedures source.

DEMONSTRATED: EUA is narrower than sci-fi "emergency pathway" rhetoric. FDA's EUA authority under FD&C Act section 564 applies when HHS declares an emergency and FDA authorizes products for serious or life-threatening diseases or conditions caused by CBRN threat agents or related circumstances, with no adequate, approved, available alternatives source. Ordinary organ shortage is a tragedy, but it is not automatically a CBRN emergency under current EUA law source.

DEMONSTRATED legal constraint: U.S. law prohibits transferring human organs for valuable consideration for transplantation if interstate commerce is affected source. That matters for any "bodyoid organ market" because regulators and courts would need to decide whether bodyoid-derived organs are "human organs" under organ-transplant law, whether manufacturing/service fees are permitted, and how consent/property rules attach to source cells source.

DEMONSTRATED regulatory arbitrage: Próspera/Roatán has hosted biohacking/gene-therapy activity. ClinicalTrials.gov lists Minicircle's phase 1 injectable follistatin plasmid gene therapy study at the GARM site on Roatán, Honduras source. Pharmaceutical Technology reported Próspera hosts biotechs working on aging-related gene therapies and markets a flexible regulatory jurisdiction source. Minicircle's own FAQ says its gene therapy is available through clinical partners in Roatán and the Bahamas and that clinical trial data are being prepared for publication source.

Hype flag: medical-tourism biotech can accelerate first-in-human experiments, but it does not make the evidence stronger. The Minicircle-style pattern is especially precarious because the public record includes ClinicalTrials.gov registration and company claims but limited peer-reviewed outcomes source, source. A Próspera-like venue might plausibly be where bodyoid or aggressive regenerative experiments first appear, but U.S./EU adoption would still require CMC, safety, long-term follow-up, transplant ethics, and probably new law.

Independent P estimates:

7. Lab-Grown Meat

Verdict: OPEN; brief worldbuilding support for cheap bioreactors is weaker than claimed.

DEMONSTRATED: cultivated meat is approved for limited U.S. sale in specific products. USDA allowed UPSIDE Foods and GOOD Meat to sell cultivated chicken in June 2023 after FDA "no questions" safety review and USDA inspection/label steps source, source. That is regulatory proof-of-entry, not proof of price parity.

DEMONSTRATED: reputable optimistic scenarios have projected cost parity by around 2030 under steep cost declines, while skeptical techno-economic analysis has emphasized major cost barriers. McKinsey projected cultivated meat could reach under $5/lb and cost parity by 2030 if costs fall rapidly with scale and manufacturing improvement source. GFI's 2026 state-of-industry summary says 2025 had both successes and struggles and that investors are focusing on fundamentals like cost, taste, and scale source.

Skeptical read: cultured meat progress helps the biopunk aesthetic, but it does not directly imply transplantable organs. Muscle cells for food are simpler than vascularized, innervated, immunologically compatible organs. Price parity by 2037 for ground/minced hybrid products is plausible; price parity for structured steaks at mass scale is less certain.

Independent P estimates:

Premise-By-Premise Scorecard

What Is Genuinely Real In Humans Now

• Pig organ transplantation: real in living humans, but experimental and durability-limited; kidney survival has reached months, not proven years source.
• FDA-cleared pig kidney trials: real for United Therapeutics UKidney and eGenesis EGEN-2784 source, source.
• External bioengineered liver assist: real phase 1 human exposure in five patients for miroliverELAP source.
• Ectopic mini-liver trial: real phase 2a human trial, early stage source.
• Spinal stimulation and BCI: real human functional recovery/routing-around, including FDA-cleared noninvasive ARC-EX and one-person implanted BSI demonstration source, source.

What Is Concept-Stage Or Hype

• Human bodyoids / organ sacs: concept-stage; no public proof that a functional organ sack exists source.
• Whole organs from scratch: research-stage; vascularization/perfusion, maturation, and surgical integration remain open source.
• Whole-body spare clones: hype unless demonstrated in animals first; current artificial-womb work is late-prematurity support, not full ectogenesis source.
• Brain-to-body transfer: not addressed by current SCI advances; digital bridges bypass damaged communication rather than reconnecting severed CNS anatomy source.
• Longevity gene-therapy tourism: legally interesting but evidentially weak when outcomes are unpublished or company-reported source.

Where The Worldbuilding Is Most Likely To Come True

The strongest 2037 version is a world of organ triage and hybrid supply chains: pig kidneys and hearts in trials or limited practice; external liver-assist machines in transplant centers; lymph-node mini-livers as bridge therapy if LyGenesis works; improved organ preservation and perfusion; and neurostimulation devices that restore partial function. That world is supported by the current clinical trajectory source, source, source.

The weakest 2037 version is a world of personal reserve bodies and routine brain integration. That needs simultaneous breakthroughs in ectogenesis, developmental patterning, vascularization, immune compatibility, legal acceptance, and CNS reconnection. No 2026 evidence demonstrates that stack source, source, source.

Highest-Leverage Places To Plug In

1. Xenotransplantation operations: immunosuppression, rejection biomarkers, pathogen surveillance, organ preservation, clinical-trial logistics, and payer/regulatory strategy. This is closest to patients now source.
2. Bioengineered organ-assist: decellularized scaffold recellularization, perfusion bioreactors, endothelialization, liver/kidney functional assays, and CMC. miroliverELAP is the key concrete example source.
3. Vascularization and perfusion engineering: microvascular networks, perfusable organoids, organ-on-chip, and computational vascular design are central bottlenecks across organoids, bioprinting, and bodyoids source.
4. Neurostimulation/BCI rehab: ARC-EX-like noninvasive systems, implanted epidural stimulation, closed-loop control, and rehab protocols are real and scalable before biological reconnection is solved source.
5. Regulatory/ethics infrastructure: xenotransplant infectious-risk governance, bodyoid legal status, NOTA interpretation, consent for source cells, and expanded-access designs will shape what can actually enter medicine source, source.

Where I Want A Second Source / Am Uncertain

• eGenesis human-case count after January 2026: eGenesis' January 2026 corporate overview says four EGEN-2784 kidney transplants had been completed under expanded access, but I would want a hospital release or peer-reviewed case report for each patient before treating all details as settled source.
• Kind Biotechnology: I found insufficient primary-source evidence during this pass to validate its role in "organ sacs"; this needs patent and corporate-document review.
• Long-term pig kidney outcomes: the public record is changing quickly; trial registries and hospital updates should be checked monthly source.
• miroliverELAP full phase 1 data: United Therapeutics says full results will be presented/published in the second half of 2026, so the current evidence is press-release level source.
• Artificial-womb human trials: FDA held an advisory meeting in 2023, but I did not verify a started human EXTEND trial by May 31, 2026 source.
• Cultivated meat economics: price-parity claims depend heavily on assumptions about media cost, capex, contamination rates, utilization, and product format; I would treat all single-year forecasts as promotional unless backed by audited production data source.

Final Skeptical Take

Biopunk 2037 is realistic if rewritten as "xenotransplant and organ-support medicine gets weird, expensive, and partially effective." It is not realistic if it requires "lab-grown spare bodies plus clean brain transfer." The former is already in FDA-cleared trials; the latter is still a stack of unsolved developmental biology, ectogenesis, ethics, and CNS wiring problems.